Core Viewpoint - The stock of Fuhong Hanlin (02696) rose nearly 5% in early trading, reflecting positive market sentiment following recent developments in clinical research and regulatory approvals [1] Group 1: Clinical Research Developments - Fuhong Hanlin successfully held an offline investigator meeting in San Francisco, focusing on the international multicenter Phase III clinical study HLX22-GC-301, which investigates the combination of the new anti-HER2 monoclonal antibody HLX22 with trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer [1] - The company announced the approval from the National Medical Products Administration for clinical trials of HLX43 in combination with HLX07 and surufatinib for the treatment of advanced solid tumors, with plans to initiate a Phase II clinical study in China once conditions are met [1]
复宏汉霖早盘涨近5% HLX22头对头K药胃癌III期临床美国研究者会顺利举行